consultantsreview logo

Consultants Review Magazine

Piramal Enterprises board approves scheme for the demerger of pharma business

Piramal Enterprises on Thursday has said that its board has approved a composite scheme of arrangement providing for the demerger of its pharmaceuticals business and simplification of the corporate structure to create two listed entities in financial services and pharmaceuticals.

The pharmaceuticals business will get vertically demerged from the Piramal Enterprises and consolidated under Piramal Pharma, the company said in a regulatory filing.

Following the demerger, Piramal Pharma will become one of the large pharma companies listed on the NSE and BSE, it added.

"In consideration of the demerger, Piramal Pharma Ltd (PPL) shall issue 4 fully paid-up equity shares of PPL of Rs 10 each to the shareholders of PEL for every 1 fully paid-up equity share in PEL having a face value of Rs 2 each held by them, in accordance with the Share Entitlement Ratio," Piramal Enterprises Ltd (PEL) said.

Two operating subsidiaries wholly-owned by Piramal Pharma will also be amalgamated with Piramal Pharma Ltd to further simplify the pharma corporate structure, it added.

Piramal Group Chairman Ajay Piramal said, over the years, Piramal Enterprises has grown multi-fold with diverse businesses under one listed holding company structure.

"In line with our stated strategy, the board has approved the demerger and simplification of our corporate structure, to create two independent listed entities in financial services and pharmaceuticals, with a leadership position across the business segments they operate in," he added.

It will firmly empower both entities to be future-ready and enable them to independently pursue their growth strategies with sharper focus and identity, Piramal said. "Piramal Pharma will be a large India-listed pharma company with proven capabilities in contract development and manufacturing, global distribution of complex hospital generics, and a large geographic footprint in the consumer products market in India," he added.

Piramal Pharma's contract development and manufacturing (CDMO) business is one of the top three in India and the 13th largest globally. PPL's complex hospital generics and India consumer healthcare businesses are well positioned with differentiated products and business models, Piramal said.

Magazine Current Issue